These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 27589570)

  • 1. Prognostic value of PDL1 expression in pancreatic cancer.
    Birnbaum DJ; Finetti P; Lopresti A; Gilabert M; Poizat F; Turrini O; Raoul JL; Delpero JR; Moutardier V; Birnbaum D; Mamessier E; Bertucci F
    Oncotarget; 2016 Nov; 7(44):71198-71210. PubMed ID: 27589570
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic and predictive value of PDL1 expression in breast cancer.
    Sabatier R; Finetti P; Mamessier E; Adelaide J; Chaffanet M; Ali HR; Viens P; Caldas C; Birnbaum D; Bertucci F
    Oncotarget; 2015 Mar; 6(7):5449-64. PubMed ID: 25669979
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PDL1 expression is an independent prognostic factor in localized GIST.
    Bertucci F; Finetti P; Mamessier E; Pantaleo MA; Astolfi A; Ostrowski J; Birnbaum D
    Oncoimmunology; 2015 May; 4(5):e1002729. PubMed ID: 26155391
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pancreatic tumors and immature immunosuppressive myeloid cells in blood and spleen: role of inhibitory co-stimulatory molecules PDL1 and CTLA4. An in vivo and in vitro study.
    Basso D; Fogar P; Falconi M; Fadi E; Sperti C; Frasson C; Greco E; Tamburrino D; Teolato S; Moz S; Bozzato D; Pelloso M; Padoan A; De Franchis G; Gnatta E; Facco M; Zambon CF; Navaglia F; Pasquali C; Basso G; Semenzato G; Pedrazzoli S; Pederzoli P; Plebani M
    PLoS One; 2013; 8(1):e54824. PubMed ID: 23359812
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the diagnostic and prognostic value of PDL1 expression in Hodgkin and B-cell lymphomas.
    Menter T; Bodmer-Haecki A; Dirnhofer S; Tzankov A
    Hum Pathol; 2016 Aug; 54():17-24. PubMed ID: 27045512
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PDL1 expression is a poor-prognosis factor in soft-tissue sarcomas.
    Bertucci F; Finetti P; Perrot D; Leroux A; Collin F; Le Cesne A; Coindre JM; Blay JY; Birnbaum D; Mamessier E
    Oncoimmunology; 2017; 6(3):e1278100. PubMed ID: 28405501
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PD1 and PDL1 expression in primary central nervous system diffuse large B-cell lymphoma are frequent and expression of PD1 predicts poor survival.
    Four M; Cacheux V; Tempier A; Platero D; Fabbro M; Marin G; Leventoux N; Rigau V; Costes-Martineau V; Szablewski V
    Hematol Oncol; 2017 Dec; 35(4):487-496. PubMed ID: 27966264
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The mechanism of de novo expression of programmed cell death-ligand 1 in squamous cell carcinoma of the lung.
    Igarashi T; Teramoto K; Ishida M; Hanaoka J; Daigo Y
    Oncol Rep; 2017 Oct; 38(4):2189-2196. PubMed ID: 28791392
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phospho‑STAT1 expression as a potential biomarker for anti‑PD‑1/anti‑PD‑L1 immunotherapy for breast cancer.
    Nakayama Y; Mimura K; Tamaki T; Shiraishi K; Kua LF; Koh V; Ohmori M; Kimura A; Inoue S; Okayama H; Suzuki Y; Nakazawa T; Ichikawa D; Kono K
    Int J Oncol; 2019 Jun; 54(6):2030-2038. PubMed ID: 31081058
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Programmed Death-1 Ligand-1 (PDL1) Expression Is Associated with the Prognosis of Patients with Stage II/III Gastric Cancer.
    Tamura T; Ohira M; Tanaka H; Muguruma K; Toyokawa T; Kubo N; Sakurai K; Amano R; Kimura K; Shibutani M; Maeda K; Hirakawa K
    Anticancer Res; 2015 Oct; 35(10):5369-76. PubMed ID: 26408698
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting of interleukin (IL)-17A inhibits PDL1 expression in tumor cells and induces anticancer immunity in an estrogen receptor-negative murine model of breast cancer.
    Ma YF; Chen C; Li D; Liu M; Lv ZW; Ji Y; Xu J
    Oncotarget; 2017 Jan; 8(5):7614-7624. PubMed ID: 27935862
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor cell expression of immune inhibitory molecules and tumor-infiltrating lymphocyte count predict cancer-specific survival in pancreatic and ampullary cancer.
    Sideras K; Biermann K; Yap K; Mancham S; Boor PPC; Hansen BE; Stoop HJA; Peppelenbosch MP; van Eijck CH; Sleijfer S; Kwekkeboom J; Bruno MJ
    Int J Cancer; 2017 Aug; 141(3):572-582. PubMed ID: 28470686
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression and significance of CD47, PD1 and PDL1 in T-cell acute lymphoblastic lymphoma/leukemia.
    Yang K; Xu J; Liu Q; Li J; Xi Y
    Pathol Res Pract; 2019 Feb; 215(2):265-271. PubMed ID: 30466764
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Upregulation of PD‑L1 expression by resveratrol and piceatannol in breast and colorectal cancer cells occurs via HDAC3/p300‑mediated NF‑κB signaling.
    Lucas J; Hsieh TC; Halicka HD; Darzynkiewicz Z; Wu JM
    Int J Oncol; 2018 Oct; 53(4):1469-1480. PubMed ID: 30066852
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Significance of
    Uhercik M; Sanders AJ; Owen S; Davies EL; Sharma AK; Jiang WG; Mokbel K
    Anticancer Res; 2017 Aug; 37(8):4249-4254. PubMed ID: 28739716
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PDL1 expression in inflammatory breast cancer is frequent and predicts for the pathological response to chemotherapy.
    Bertucci F; Finetti P; Colpaert C; Mamessier E; Parizel M; Dirix L; Viens P; Birnbaum D; van Laere S
    Oncotarget; 2015 May; 6(15):13506-19. PubMed ID: 25940795
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic value of stromal tumour infiltrating lymphocytes and programmed cell death-ligand 1 expression in breast cancer.
    Polónia A; Pinto R; Cameselle-Teijeiro JF; Schmitt FC; Paredes J
    J Clin Pathol; 2017 Oct; 70(10):860-867. PubMed ID: 28373294
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictive and prognostic value of PDL1 protein expression in breast cancer patients in neoadjuvant setting.
    Wu Z; Zhang L; Peng J; Xu S; Zhou L; Lin Y; Wang Y; Lu J; Yin W; Lu J
    Cancer Biol Ther; 2019; 20(6):941-947. PubMed ID: 30866717
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Macrocyclic Compounds from Ansamycin Antibiotic Class as Inhibitors of PD1-PDL1 Protein-Protein Interaction.
    Patil SP; Yoon SC; Aradhya AG; Hofer J; Fink MA; Enley ES; Fisher JE; Herb MC; Klingos A; Proulx JT; Fedorky MT
    Chem Pharm Bull (Tokyo); 2018; 66(8):773-778. PubMed ID: 30068796
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CTHRC1 and PD‑1/PD‑L1 expression predicts tumor recurrence in prostate cancer.
    Zhou Q; Xiong W; Zhou X; Gao RS; Lin QF; Liu HY; Li JN; Tian XF
    Mol Med Rep; 2019 Nov; 20(5):4244-4252. PubMed ID: 31545446
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.